Novel bispecific CAR-T therapy C-CAR168 targeting CD20/BCMA demonstrated positive safety profile with only low-grade cytokine release syndrome in early clinical trials for autoimmune diseases.
AbelZeta Pharma presented preclinical data for C-CAR168, a novel bispecific CAR-T therapy targeting both CD20 and BCMA for treatment-resistant lupus nephritis and SLE at ACR Convergence 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.